Harnessing The Power of
NK Cells to Defeat Cancer


"Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2021, moving towards broad patient access to cancer-defeating cures."

- Dr. Daniel Teper, Cytovia Therapeutics CEO


Cytovia In The News


Watch a replay of the Cell Therapy panel at the 10th Annual LifeSci Partners Corporate Access Event, featuring our CEO Dr. Daniel Teper

January 7th, 2021

Watch a replay of Cytovia's recent fireside chat at the RBC Capital Markets Healthcare Conference, featuring CEO Dr. Daniel Teper and CSO Dr. Wei Li

December 16th, 2020

Subscribe Form

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube